Growing uncertainty over efficacy of China made Sinovac

NEW DELHI: Uncertainty is on the rise over the efficacy of the Sinovac produced in China.

The Sinovac allegedly has shown four different efficacy rates during clinical trials ranging from over 91 to 50 per cent. The global scientific community is still sceptical about its use.

In Indonesia President Joko Widodo on Wednesday received the Chinese made vaccine on Live television. Turkey conducted a local trial of Sinovac but pool was small.

Sinovac has been found to be 50.4% effective in Brazilian clinical trials, according to the latest results released by researchers. It shows the vaccine is significantly less effective than previous data suggested – barely over the 50% needed for regulatory approval, BBC reported.

Last week researchers at the Butantan Institute, which has been conducting the trials in Brazil, announced that the vaccine had a 78% efficacy against “mild-to-severe” Covid-19 cases.

But on Tuesday they revealed that calculations for this figure did not include data…

Exit mobile version